Estrofem 1 mg & 2 mg FC tablets.
PDF Leaflet Revision Date: 17 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of symptoms due to estrogen deficiency in hysterectomised patients.
Dosage (summary)
1 mg to 2 mg daily, starting with the lowest effective dose.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated during pregnancy and lactation.
Key Drug Interactions
- Anticonvulsants
- Rifampicin
- St John's wort
Contraindications
- Pregnancy
- Breast cancer
- Estrogen-dependent tumors
- Undiagnosed genital bleeding
- Active liver disease
- Thromboembolic disorders
Common side effects
- Breast tenderness
- Abdominal pain
- Oedema
- Headache
Counselling Points
- Take at the same time daily
- Report any unusual breast changes
- Regular check-ups recommended
Serious warnings
- Increased risk of endometrial cancer with prolonged use
- Increased risk of venous thromboembolism
- Monitor for signs of depression
Important Disclaimer
The Estrofem 1 mg & 2 mg FC tablets. professional information leaflet below is the property of Novo Nordisk and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
